Abbott Delivers Strong Q2 Sales, Led By Spike In FreeStyle Libre Sales
Executive Summary
Abbott delivered solid sales growth in the second quarter of 2019, topping analyst expectations. The company reported worldwide sales of $8bn, up 2.7% with Medical Devices highlighted as a standout division, delivering 10.5% organic growth.
You may also be interested in...
Diabetes, Mitral Repair And Diagnostics Drive Big Quarter For Abbott
Abbott Laboratories’ medical device businesses grew 10.6% year over year in the third quarter of 2019 while its diagnostics business grew 6.6%, helping the company grow 7.6% overall, the company reported on 16 October.
Abbott Signs Partnership With Omada To Expand FreeStyle Libre Users
Abbott signed a deal with Omada Health to integrate Abbott's FreeStyle Libre with Omada's health coaching platform.
Abbott And Sanofi To Connect Diabetes Technologies
Abbott and Sanofi are partnering up to develop a new connected diabetes device. The non exclusive collaboration will combine Abbott’s FreeStyle Libre continuous glucose monitoring system with Sanofi’s connected insulin pens and software currently under development.